tetano
Editor, Senior Moderator
Int J Infect Dis
. 2021 May 23;S1201-9712(21)00420-3.
doi: 10.1016/j.ijid.2021.05.019. Online ahead of print.
Candesartan as a tentative treatment for COVID-19: a prospective non-randomized open-label study
Antonia Anna Lukito[SUP] 1 [/SUP], Allen Widysanto[SUP] 2 [/SUP], Theo Audi Yanto Lemuel[SUP] 2 [/SUP], Ignatius Bima Prasetya[SUP] 2 [/SUP], Billy Massie[SUP] 2 [/SUP], Mira Yuniarti[SUP] 2 [/SUP], Nicolaski Lumbuun[SUP] 3 [/SUP], Raymond Pranata[SUP] 3 [/SUP], Cindy Meidy[SUP] 3 [/SUP], Eka Julianta Wahjoepramono[SUP] 2 [/SUP], Irawan Yusuf[SUP] 4 [/SUP]
Affiliations
Abstract
Background: This study aimed to investigate whether the addition of candesartan to the standard care regimen improved the outcome in patients with coronavirus 2019 (COVID-19).
Methods: A prospective non-randomized open-label study was undertaken from May to August 2020 on 75 subjects (aged 18-70 years) hospitalized in Siloam Kelapa Dua Hospital. Uni- and multi-variable Cox regression analyses were performed to obtain hazard ratios (HRs). The primary outcomes were: (1) length of hospital stay; (2) time to negative swab; and (3) radiological outcome (time to improvement on chest x ray).
Results: None of the 75 patients with COVID-19 required intensive care. All patients were angiotensin-receptor-blocker naïve. In comparison with the control group, the candesartan group had a significantly shorter hospital stay [adjusted HR 2.47, 95% confidence interval (CI) 1.16-5.29] after adjusting for a wide range of confounders, and no increased risk of intensive care. In the non-obese subgroup, the candesartan group had a shorter time to negative swab (unadjusted HR 2.11, 95% CI 1.02-4.36; adjusted HR 2.40, 95% CI 1.08-5.09) and shorter time to improvement in chest x ray (adjusted HR 2.82, 95% CI 1.13-7.03) compared with the control group.
Conclusion: Candesartan significantly reduces the length of hospital stay after adjustment for covariates. All primary outcomes improved significantly in the non-obese subgroup receiving candesartan.
Keywords: Angiotensin; Candesartan; Coronavirus; SARS-CoV-2; Severity.
. 2021 May 23;S1201-9712(21)00420-3.
doi: 10.1016/j.ijid.2021.05.019. Online ahead of print.
Candesartan as a tentative treatment for COVID-19: a prospective non-randomized open-label study
Antonia Anna Lukito[SUP] 1 [/SUP], Allen Widysanto[SUP] 2 [/SUP], Theo Audi Yanto Lemuel[SUP] 2 [/SUP], Ignatius Bima Prasetya[SUP] 2 [/SUP], Billy Massie[SUP] 2 [/SUP], Mira Yuniarti[SUP] 2 [/SUP], Nicolaski Lumbuun[SUP] 3 [/SUP], Raymond Pranata[SUP] 3 [/SUP], Cindy Meidy[SUP] 3 [/SUP], Eka Julianta Wahjoepramono[SUP] 2 [/SUP], Irawan Yusuf[SUP] 4 [/SUP]
Affiliations
- PMID: 34038766
- DOI: 10.1016/j.ijid.2021.05.019
Abstract
Background: This study aimed to investigate whether the addition of candesartan to the standard care regimen improved the outcome in patients with coronavirus 2019 (COVID-19).
Methods: A prospective non-randomized open-label study was undertaken from May to August 2020 on 75 subjects (aged 18-70 years) hospitalized in Siloam Kelapa Dua Hospital. Uni- and multi-variable Cox regression analyses were performed to obtain hazard ratios (HRs). The primary outcomes were: (1) length of hospital stay; (2) time to negative swab; and (3) radiological outcome (time to improvement on chest x ray).
Results: None of the 75 patients with COVID-19 required intensive care. All patients were angiotensin-receptor-blocker naïve. In comparison with the control group, the candesartan group had a significantly shorter hospital stay [adjusted HR 2.47, 95% confidence interval (CI) 1.16-5.29] after adjusting for a wide range of confounders, and no increased risk of intensive care. In the non-obese subgroup, the candesartan group had a shorter time to negative swab (unadjusted HR 2.11, 95% CI 1.02-4.36; adjusted HR 2.40, 95% CI 1.08-5.09) and shorter time to improvement in chest x ray (adjusted HR 2.82, 95% CI 1.13-7.03) compared with the control group.
Conclusion: Candesartan significantly reduces the length of hospital stay after adjustment for covariates. All primary outcomes improved significantly in the non-obese subgroup receiving candesartan.
Keywords: Angiotensin; Candesartan; Coronavirus; SARS-CoV-2; Severity.